Needham & Company LLC reissued their buy rating on shares of Personalis (NASDAQ:PSNL - Free Report) in a research note released on Thursday morning, Benzinga reports. They currently have a $3.50 target price on the stock.
Separately, Lake Street Capital assumed coverage on Personalis in a research report on Tuesday, April 30th. They set a buy rating and a $4.00 price target on the stock.
Get Our Latest Analysis on Personalis
Personalis Trading Up 5.4 %
PSNL traded up $0.09 on Thursday, hitting $1.65. 419,660 shares of the stock traded hands, compared to its average volume of 361,073. Personalis has a 52 week low of $0.89 and a 52 week high of $2.60. The firm has a market capitalization of $83.33 million, a PE ratio of -0.73 and a beta of 1.91. The business has a fifty day moving average price of $1.48 and a two-hundred day moving average price of $1.45.
Personalis (NASDAQ:PSNL - Get Free Report) last released its quarterly earnings data on Wednesday, February 28th. The company reported ($0.46) earnings per share for the quarter, beating the consensus estimate of ($0.53) by $0.07. Personalis had a negative return on equity of 61.42% and a negative net margin of 147.38%. The company had revenue of $19.68 million for the quarter, compared to analyst estimates of $19.56 million. On average, equities research analysts forecast that Personalis will post -1.58 EPS for the current fiscal year.
Institutional Inflows and Outflows
Several large investors have recently bought and sold shares of the company. Prime Capital Investment Advisors LLC acquired a new position in shares of Personalis in the 3rd quarter valued at $36,000. Pathstone Family Office LLC lifted its stake in shares of Personalis by 149.3% in the 3rd quarter. Pathstone Family Office LLC now owns 37,081 shares of the company's stock valued at $45,000 after purchasing an additional 22,204 shares during the period. Quadrature Capital Ltd acquired a new position in shares of Personalis in the 4th quarter valued at $152,000. Howland Capital Management LLC lifted its stake in shares of Personalis by 392.8% in the 1st quarter. Howland Capital Management LLC now owns 211,118 shares of the company's stock valued at $315,000 after purchasing an additional 168,274 shares during the period. Finally, GSA Capital Partners LLP raised its stake in Personalis by 6.2% during the 1st quarter. GSA Capital Partners LLP now owns 420,141 shares of the company's stock worth $626,000 after buying an additional 24,498 shares during the period. Institutional investors and hedge funds own 61.91% of the company's stock.
About Personalis
(
Get Free Report)
Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.
Featured Articles
Before you consider Personalis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Personalis wasn't on the list.
While Personalis currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
